1. Home
  2. PRPO vs NRSN Comparison

PRPO vs NRSN Comparison

Compare PRPO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • NRSN
  • Stock Information
  • Founded
  • PRPO N/A
  • NRSN 2017
  • Country
  • PRPO United States
  • NRSN Israel
  • Employees
  • PRPO N/A
  • NRSN N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • NRSN Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRPO Industrials
  • NRSN Health Care
  • Exchange
  • PRPO Nasdaq
  • NRSN Nasdaq
  • Market Cap
  • PRPO 30.2M
  • NRSN 29.8M
  • IPO Year
  • PRPO N/A
  • NRSN 2021
  • Fundamental
  • Price
  • PRPO $20.66
  • NRSN $1.07
  • Analyst Decision
  • PRPO
  • NRSN Buy
  • Analyst Count
  • PRPO 0
  • NRSN 2
  • Target Price
  • PRPO N/A
  • NRSN $14.00
  • AVG Volume (30 Days)
  • PRPO 15.0K
  • NRSN 249.5K
  • Earning Date
  • PRPO 11-06-2025
  • NRSN 12-17-2025
  • Dividend Yield
  • PRPO N/A
  • NRSN N/A
  • EPS Growth
  • PRPO N/A
  • NRSN N/A
  • EPS
  • PRPO N/A
  • NRSN N/A
  • Revenue
  • PRPO $21,242,000.00
  • NRSN N/A
  • Revenue This Year
  • PRPO N/A
  • NRSN N/A
  • Revenue Next Year
  • PRPO N/A
  • NRSN N/A
  • P/E Ratio
  • PRPO N/A
  • NRSN N/A
  • Revenue Growth
  • PRPO 27.05
  • NRSN N/A
  • 52 Week Low
  • PRPO $3.90
  • NRSN $0.80
  • 52 Week High
  • PRPO $22.38
  • NRSN $2.60
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 57.34
  • NRSN 39.08
  • Support Level
  • PRPO $16.40
  • NRSN $1.05
  • Resistance Level
  • PRPO $21.67
  • NRSN $1.30
  • Average True Range (ATR)
  • PRPO 1.46
  • NRSN 0.07
  • MACD
  • PRPO 0.10
  • NRSN -0.01
  • Stochastic Oscillator
  • PRPO 75.98
  • NRSN 20.41

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: